• 글쓰기
• 목록

ADHD Medication During Pregnancy and Breastfeeding

Women suffering from ADHD have to make a difficult choice about whether to continue or stop taking ADHD medication during pregnancy and breastfeeding. Little data exists about how long-term exposure to these medications may affect the foetus.

A study recently published in Molecular Psychiatry shows that children exposed to ADHD medication during the uterus do not develop neurological developmental disorders like hearing loss or impaired vision seizures, febrile seizures or IQ impairment. The authors acknowledge that further high-quality studies are required.

Risk/Benefit Analysis

Women who are pregnant and taking ADHD medication should consider the benefits of taking it against the potential risks for the baby. Physicians don't have the data to make unambiguous recommendations, but can provide information on risks and benefits to help pregnant women make informed choices.

A study published in Molecular Psychiatry found that women who used ADHD medications in early pregnancy did not have a significantly increased risk of fetal cardiac malformations or major birth defects that are structural. The researchers used a large population-based study of case-control to determine the prevalence of major structural birth defects in infants born to mothers who had taken stimulants during the early stages of pregnancy and those who had not. Clinical geneticists, pediatric cardiologists and other experts examined the cases to make sure that the classification was accurate and to reduce any bias.

The study of the researchers was not without its limitations. The researchers were unable, in the first place to distinguish the effects caused by the medication from the disorder. This makes it difficult for researchers to determine if the few associations observed between the groups that were exposed to the use of medication or confounded by comorbidities. Additionally, the researchers did not study the long-term outcomes of offspring.

The study did reveal that babies whose mothers had taken ADHD medications during pregnancy were at a slightly greater risk of being admitted to the neonatal intensive care unit (NICU) than those who were born without any medication or taken off their medication prior to or during pregnancy. This increase was due to central nervous system disorders, and the increased risk types of adhd medication admission did not appear to be affected by the type of stimulant medications were used during pregnancy.

Women who used stimulant ADHD medication during pregnancy also had an increased chance of having a caesarean birth or having a baby born with low Apgar score (less than 7). These increases didn't seem to be influenced by the type of medication that was used during pregnancy.

Researchers suggest that the small risks posed by the use of ADHD medication during pregnancies in the early stages can be offset by more beneficial outcomes for both baby and mother of continued treatment for the woman's condition. Physicians should discuss this with their patients and, where possible, help them develop strategies to improve coping skills which can reduce the effects of her disorder on her daily functioning and relationships.

Interactions with Medication

Doctors are increasingly faced with the decision of whether to maintain treatment or stop during pregnancy as more women are diagnosed with ADHD. These decisions are frequently taken without clear and authoritative evidence. Instead, doctors must take into account their own experience, the experience of other doctors, and the research on the subject.

Particularly, the issue of potential risks to the baby can be a challenge. The research on this subject is based on observation rather than controlled studies and the results are in conflict. Additionally, the majority of studies limit their analysis to live births, which can underestimate severe teratogenic effects that result in abortion or termination of the pregnancy. The study discussed in this journal club addresses these limitations by analyzing data on live and deceased births.

Conclusion: While some studies have shown an association between ADHD medications and certain birth defects however, other studies haven't shown such a relationship. The majority of studies show that there is a neutral, or slightly negative, effect. In all cases an in-depth analysis of the benefits and risks must be performed.

It can be challenging, if not impossible, for women suffering from ADHD to stop taking their medication. In a recent article in Archives of Women's Mental Health by psychologist Jennifer Russell, she notes that stopping Adhd Medication Pregnancy medications during pregnancy can lead to depression and feelings of isolation. The loss of medication can also impact the ability to safely drive and perform work-related tasks, which are essential aspects of normal life for those with ADHD.

She suggests that women who are unsure whether to continue taking medication or discontinue it due to pregnancy educate family members, colleagues, and acquaintances about the condition, the effects on daily functioning, and the benefits of keeping the current treatment. It will also help a woman feel supported in her decision. It is important to note that some medications are able to be absorbed through the placenta therefore, if a patient decides to stop taking her ADHD medication during pregnancy and breastfeeding, she should be aware of the possibility that traces of the medication could be transferred to the infant.

Birth Defects and Risk of

As the use of ADHD medication to treat the symptoms of attention deficit hyperactivity disorder (ADHD) increases there are concerns about the effects that the drugs might have on foetuses. Recent research published in the journal Molecular Psychiatry has added to the body of knowledge regarding this issue. With two massive data sets, researchers were able to examine more than 4.3 million pregnancies and see whether the use of stimulant medications increased the risk of birth defects. Researchers discovered that, while the overall risk is low, the first trimester ADHD medication exposure was associated with slightly higher risk of certain heart defects, like ventriculoseptal defect.

The researchers behind the study found no association between the use of early medications and other congenital abnormalities, such as facial clefting or club foot. The results are consistent with previous studies showing an increase, but not significant, in the risk of developing cardiac malformations among women who began taking strongest adhd medication for adults medications before pregnancy. This risk increased in the later part of pregnancy, when a lot of women begin to discontinue their ADHD medications.

Women who took ADHD medication during the first trimester were more likely need a caesarean or have an insufficient Apgar after delivery and have a baby who needed breathing assistance at birth. However the authors of the study were not able to eliminate selection bias by restricting the study to women who didn't have other medical issues that could have contributed to these findings.

The researchers hope that their research will help inform the clinical decisions of doctors who see pregnant women. The researchers suggest that, while discussing the risks and benefits are important, the decision regarding whether or not to stop medication should be made according to the severity of each woman's ADHD symptoms and her needs.

The authors also advise that, while stopping the medication is an option, it is not an option to consider due to the high rate of depression and other mental health issues among women who are pregnant or post-partum. Research has also shown that women who stop taking their medication will have a difficult time adjusting to a life without them after the baby is born.

Nursing

The responsibilities that come with being a new mom can be overwhelming. Women who suffer from ADHD who have to deal with their symptoms while attending doctor appointments, making preparations for the arrival of a baby and getting used to new routines at home can experience severe challenges. As such, many women choose to continue taking their ADHD medications throughout the course of pregnancy.

The majority of stimulant medications are absorbed by breast milk in very small amounts, therefore the risk for infant who is breastfeeding is low. However, the amount of medication exposure to the newborn can vary depending on dosage, how often it is taken and at what time the medication is administered. Additionally, individual medications enter the body of the baby differently through the gastrointestinal tract and breast milk. The impact of this on a newborn is not fully understood.

Some physicians may discontinue stimulant medication during a woman's pregnancy due to the lack of research. It is a difficult decision for the mother, who must weigh the advantages of taking her medication as well as the risks to the fetus. As long as more information is available, GPs can inquire about pregnant patients whether they have an background of ADHD or if they are planning to take medication in the perinatal stage.

Many studies have shown that women can continue taking their ADHD medication safely during pregnancy and while breast-feeding. As a result, many patients choose to do so and, after consulting with their doctor, they have found that the benefits of keeping their current medication exceed any risk.

It is essential for women with ADHD who are considering breastfeeding to seek a specialist psychiatrist's advice prior to becoming pregnant. They should discuss their medication with their doctor as well as the pros and cons of continuing treatment. This includes non-pharmacological strategies. Psychoeducation is also required to help pregnant women suffering from adhd anxiety medication recognize the signs and underlying disorder. They should also learn about treatment options and build strategies for coping. This should be a multidisciplinary approach with the GPs, obstetricians and psychiatry. The pregnancy counselling should consist of discussion of a management plan for both the mother as well as the child, monitoring for signs of deterioration and when necessary, making adjustments to the medication regimen.